Five notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).
Jennifer Leavitt, MS
Advertisement
Articles by Jennifer Leavitt, MS
Most recently, the FDA approved cabozantinib for the treatment of HCC, but this drug has a history.
Here, we look at the currently open and recruiting clinical trials that focus on the role of the microbiome in colorectal cancer.
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
Introducing the new ONCOLOGY, with a new team and a new look.
Advertisement
Latest Updated Articles
Welcome to the New Face of OncologyPublished: October 29th 2018 | Updated:
Key Advances in Oncology, 2018Published: January 17th 2019 | Updated:
Oncology Conference Highlights, Q4Published: January 17th 2019 | Updated:
The Microbiome and Colorectal Cancer: Current Clinical TrialsPublished: February 15th 2019 | Updated:
- Submission Guidelines ONCOLOGY journal, CancerNetwork.com
Published: September 10th 2019 | Updated:
- FDA Approved Uses of Cabozantinib
Published: September 20th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care
4
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
5
